THE Novavax could be approved for use in the UK within weeks as late-stage trials suggested it was 89% effective in preventing coronavirus.

The UK has secured 60 million doses of the Novavax jab – to be produced on Teesside – which is believed to offer protection against the new UK and South African variants.

The vaccine was trialled at National Patient Recruitment Centre in Blackpool, one of five trial centres which opened last autumn across England.

The centre was hosted by Blackpool Teaching Hospital NHS Foundation Trust and funded by the National Institute for Health Research (NIHR).

Two vaccines have already been rolled out in the UK – from Pfizer and Oxford/AstraZeneca – while a third from Moderna has been approved for use.

In Lancashire and South Cumbria, over 80,000 vaccines have already been delivered, with nearly 90 per cent of over 80s having been vaccinated against the virus.

Read More: 80,491 have received first dose of vaccine in Lancashire and South Cumbria

The Novavax jab has shown to be 89.3% effective at preventing coronavirus in participants in its Phase 3 clinical trial in the UK, which involved more than 15,000 people aged between 18-84, of which 27% were older than 65, Novavax said.

The vaccine will now be assessed by the Medicines and Healthcare products Regulatory Agency (MHRA), Prime Minister Boris Johnson confirmed, as he thanked volunteers who made the results possible.

Stan Erck, chief executive of Novavax, told the BBC the manufacturing plant in Stockton-on-Tees should be up and running by March or April, with the company hoping to get approval for the vaccine from the MHRA around the same time.

The chairman of the Government’s Vaccine Taskforce, Clive Dix, said the results were “spectacular”, adding: “The efficacy shown against the emerging variants is also extremely encouraging.

“This is an incredible achievement that will ensure we can protect individuals in the UK and the rest of the world from this virus.”

The jab has shown around 60% effectiveness against the South African variant, which has been worrying scientists due to concerns vaccines may not work against it, but it offered 86% protection against the new UK strain.

The Novavax jab would be delivered in the second half of 2021 if it receives MHRA approval.